Payment overview · 2025
General Payments
$1,903.28
99 reported records · 27 companies
Healthcare provider profile · identity verified
Viney Soni, M.D
Allopathic & Osteopathic Physicians|Internal Medicine · FOUNTAIN VALLEY, CA · NPI 1447341409
Verified facts
What the public records show
CMS Open Payments records show Viney Soni, M.D received $1,903.28 in general payments during 2025 across 99 reported records.
GlaxoSmithKline, LLC. accounted for 16.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 41 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 193 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $308.66 | 16.2% | 21 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $185.91 | 9.8% | 9 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $177.92 | 9.3% | 14 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $154.08 | 8.1% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $139.29 | 7.3% | 10 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $119.95 | 6.3% | 5 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $86.38 | 4.5% | 4 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $69.51 | 3.6% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $68.49 | 3.6% | 2 | 2025 |
| BIOTRONIK NRO, Inc. | Unresolved — no canonical attribution shown | $64.83 | 3.4% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $55.55 | 2.9% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $54.93 | 2.9% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $46.13 | 2.4% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.82 | 2.4% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $43.42 | 2.3% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $30.65 | 1.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.25 | 1.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $28.43 | 1.5% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $25.10 | 1.3% | 1 | 2025 |
| DePuy Synthes Sales Inc. | Unresolved — no canonical attribution shown | $24.27 | 1.3% | 1 | 2025 |
| Saluda Medical Americas, Inc. | Unresolved — no canonical attribution shown | $23.94 | 1.3% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $23.87 | 1.2% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.94 | 1.2% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $20.83 | 1.1% | 1 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $20.27 | 1.1% | 1 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $20.05 | 1.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.81 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,885.90 | 98 |
| Education | $17.38 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $185.91 | 9 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $178.77 | 15 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $160.54 | 13 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $129.89 | 6 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $119.95 | 5 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $78.10 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $75.98 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $75.98 | 3 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $69.51 | 2 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $69.51 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $68.49 | 2 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $67.19 | 3 | 2025 |
Source payment records
|
|||||
| Prospera Normalized: prospera |
Device | BIOTRONIK NRO, Inc. | $64.83 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $63.42 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $55.55 | 3 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $53.27 | 5 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc. | $53.10 | 4 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $46.13 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $30.76 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $30.65 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $29.25 | 1 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $28.43 | 1 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $25.25 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $25.25 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $25.10 | 1 | 2025 |
Source payment records
|
|||||
| ORTHOVISC Normalized: orthovisc |
Device | DePuy Synthes Sales Inc. | $24.27 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $24.17 | 1 | 2025 |
Source payment records
|
|||||
| Evoke Normalized: evoke |
Device | Saluda Medical Americas, Inc. | $23.94 | 1 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $23.87 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $23.07 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $22.94 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $22.77 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $22.77 | 2 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $21.75 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $20.83 | 1 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $20.27 | 1 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $20.05 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.19 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.17 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $13.81 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $13.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 193 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
31 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
25 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
82 | 22 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
193 | 41 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
116 | 29 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 484 | 143 |
| Levothyroxine Sodium | Levothyroxine Sodium | 361 | 90 |
| Metformin Hcl | Metformin Hcl | 252 | 77 |
| Amlodipine Besylate | Amlodipine Besylate | 230 | 71 |
| Lisinopril | Lisinopril | 209 | 62 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 207 | 85 |
| Omeprazole | Omeprazole | 200 | 55 |
| Losartan Potassium | Losartan Potassium | 194 | 54 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 193 | 41 |
| Furosemide | Furosemide | 172 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 140 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 137 | 32 |
| Azithromycin | Azithromycin | 131 | 95 |
| Gabapentin | Gabapentin | 129 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 122 | 37 |
| Eliquis | Apixaban | 116 | 29 |
| Simvastatin | Simvastatin | 103 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 97 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 96 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 94 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 92 | 26 |
| Trazodone Hcl | Trazodone Hcl | 89 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 85 | 25 |
| Jardiance | Empagliflozin | 82 | 22 |
| Potassium Chloride | Potassium Chloride | 82 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 81 | 18 |
| Metformin Hcl Er | Metformin Hcl | 81 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 80 | 17 |
| Allopurinol | Allopurinol | 70 | 17 |
| Lorazepam | Lorazepam | 70 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 66 | 41 |
| Carvedilol | Carvedilol | 64 | 17 |
| Diazepam | Diazepam | 63 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 60 | suppressed |
| Alprazolam | Alprazolam | 58 | 19 |
| Montelukast Sodium | Montelukast Sodium | 58 | 19 |
| Naproxen | Naproxen | 58 | 21 |
| Januvia | Sitagliptin Phosphate | 55 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 53 | 21 |
| Vascepa | Icosapent Ethyl | 51 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 50 | suppressed |
| Famotidine | Famotidine | 49 | 16 |
| Lactulose | Lactulose | 49 | 11 |
| Atenolol | Atenolol | 48 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 44 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 44 | 23 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 43 | 14 |
| Finasteride | Finasteride | 43 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 42 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 41 | 12 |
| Clonidine Hcl | Clonidine Hcl | 37 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 36 | suppressed |
| Levetiracetam | Levetiracetam | 35 | suppressed |
| Cephalexin | Cephalexin | 34 | 30 |
| Meclizine Hcl | Meclizine Hcl | 34 | 14 |
| Prednisone | Prednisone | 34 | 23 |
| Ezetimibe | Ezetimibe | 33 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 31 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 31 | suppressed |
| Synthroid | Levothyroxine Sodium | 31 | 11 |
| Lacosamide | Lacosamide | 30 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 30 | 15 |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 27 |
| Gemfibrozil | Gemfibrozil | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Fluconazole | Fluconazole | 28 | 18 |
| Glipizide | Glipizide | 28 | suppressed |
| Ibuprofen | Ibuprofen | 28 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 26 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Meloxicam | Meloxicam | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 25 | 13 |
| Acyclovir | Acyclovir | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Nystatin | Nystatin | 23 | 14 |
| Tradjenta | Linagliptin | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 19 |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 18 |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 18 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 15 |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Xopenex Hfa | Levalbuterol Tartrate | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Lubiprostone | Lubiprostone | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 15 |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 15 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 15 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Ramelteon | Ramelteon | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Quviviq | Daridorexant Hcl | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Orphenadrine Citrate Er | Orphenadrine Citrate | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Levemir | Insulin Detemir | 11 | suppressed |
| Lexapro | Escitalopram Oxalate | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,903.28 · 99 records | GlaxoSmithKline, LLC. | AIRSUPRA, Arikayce, Auvelity, Belbuca, Brinsupri, COSENTYX, DUPIXENT, EVENITY, Evoke, JAKAFI, JASCAYD, JOURNAVX, KEVEYIS, NUCALA, OCTAGAM IMMUNE GLOBULIN (HUMAN), OFEV, OPSUMIT, ORTHOVISC, OTEZLA, PANZYGA, PROLIA, PURIFIED CORTROPHIN GEL, Prolastin-C Liquid, Prospera, QULIPTA, QUTENZA, RELISTOR, REPATHA, RINVOQ, SMARTVEST, Senza, Symbravo, TEZSPIRE, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, Tymlos, UBRELVY, UPTRAVI, XIFAXAN, YUPELRI, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error